Abstract:Key PointsExploration for biomarkers for drugs that block immune checkpoints should be rationally conducted based on knowledge of the mechanism of action of the targeted pathway. The programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte associated antigen 4 (CTLA4) pathways are unique, and there are special considerations based on mechanisms of action for developing biomarkers for drugs blocking each of these pathways.Biomarkers for immune checkpoint-blocking drugs currently fall into three major categories: immunological, genetic and virological. Future work may reveal additional markers related to metabolism and the microbiome.Immunological biomarkers offer the advantage of applicability across multiple tumour types amenable to immune checkpoint blockade. In the case of anti-PD1 drugs, tumour PD1 ligand 1 (PDL1) expression is a pretreatment biomarker that predicts a greater likelihood of response to therapy. Despite technical pitfalls that make clinical application challenging, two PDL1 immunohistochemistry tests are currently approved by the US Food and Drug Administration for guiding treatment decisions in patients with non-small-cell lung cancer and melanoma.Although no specific oncogene or driver mutation has yet been correlated with clinical response to immune checkpoint blockade, overall tumour mutational burden reflecting neoantigenic diversity may have predictive value. This is exemplified by the high anti-PD1 response rate in DNA mismatch repair deficient colorectal cancers (which have a large mutational burden and which account for ∼15% of all colon cancers), whereas mismatch repair proficient colon cancers are unlikely to respond.Virus-associated cancers, which account for more than 20% of cancers worldwide, express viral neoantigens that are strongly immunogenic. Early evidence demonstrates expression of PD1–PDL1 in these cancers, and suggests responsiveness to anti-PD1 therapies.Combination treatment regimens based on immune checkpoint-blocking drugs are emerging as the next step in clinical development to improve efficacy and response durability. Biomarker considerations for these regimens are complex and are likely to involve multifactorial assessments.

Biomarkers of response to PD-1/PD-L1 inhibition

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges

Immune checkpoint inhibitors: recent progress and potential biomarkers

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Biomarkers for response to immunotherapy in hepatobiliary malignancies

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Advances and prospects of biomarkers for immune checkpoint inhibitors

Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma

Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway.

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?

Progresses in biomarkers for cancer immunotherapy